ClearNote Health targets early pancreatic cancer detection with multi-analyte blood test data
ClearNote Health will present Avantect pancreatic cancer test validation data at ASCO 2026. Find out what it could mean for early detection.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Guardant Health brings Shield multi-cancer detection test to Asia through Manulife insurer deal
Guardant Health partners with Manulife to launch its Shield MCD blood test in Hong Kong, Singapore and the Philippines. Analysis of what this means for oncology.
Medical Devices & Diagnostics
Can ClearNote Health’s Avantect test finally close the early detection gap in pancreatic cancer
ClearNote Health’s updated Avantect test improves pancreatic cancer detection in high-risk patients. Find out what this changes for early screening strategies.